Sanofi requests removal of Tzield from CNPV program after Høeg gets involved

RegulatoryTzieldNegative

AI Analysis

Summary

Sanofi has requested removal of Tzield from the CNPV program after Acting CDER Director Tracy Beth Høeg reportedly disagreed with FDA staff who supported approval of the type 1 diabetes drug.

Outcome Details

Sanofi requests removal from CNPV program; Acting CDER Director Tracy Beth Høeg reportedly disagreed with staff approval recommendation

Importance:6/10

Sentiment:

-0.70

FDAregulatorytype 1 diabetesCDERpolitical appointeedrug approval

Related Companies

$SNY

Read the original article

Published by BioSpace on May 7, 2026 1:04 PM

Read Original